Collaborative care shows promise for opioid and alcohol use disorders

Science Spotlight

This is Archived Content. This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA). View current news releases on nida.nih.gov.

A NIDA-funded randomized clinical trial found that primary care patients with opioid and alcohol use disorders (OAUD) who were offered a collaborative care intervention were more likely to receive evidence-based treatment and refrain from using opioids and alcohol six months later, compared to patients receiving usual care.

Dr writing a prescriptionSource: Footage Firm, Inc

The collaborative care intervention increased both the proportion of patients receiving evidence-based treatment for OAUD (39.0% vs. 16.8%) and the number refraining from opioids or alcohol use at six months. (32.8% vs. 22.3%). Collaborative care was designed to increase the delivery of either a six-session brief psychotherapy treatment, and/or medication-assisted treatment, with either buprenorphine/naloxone for opioid use disorders or long-acting injectable naltrexone for alcohol use disorders. Usual care participants were given a number for appointment scheduling and a list of community referrals for OAUD treatment.

The authors suggest the findings indicate that treatment for OAUDs can be integrated into primary care settings effectively.

For a copy of the paper go to — "Collaborative Care for Opioid and Alcohol Use Disorders in Primary Care: The SUMMIT Randomized Clinical Trial"— published in JAMA Internal Medicine.

For information about opioids, go to: https://www.drugabuse.gov/drugs-abuse/opioids. For information about alcohol, go to: https://www.drugabuse.gov/drugs-abuse/alcohol.

For more information, contact the NIDA press office at media@nida.nih.gov or 301-443-6245. Follow NIDA on Twitter and Facebook